Maxim analyst Michael Okunewitch raised the firm’s price target on Definium Therapeutics (DFTX) to $40 from $18 and keeps a Buy rating on the shares after its Q4 results. The company’s cash on the balance sheet should provide sufficient funding into 2028, through a busy 2026 with three Phase 3 pivotal readouts for DT120, the analyst tells investors in a research note. As the readout in MDD – major depressive disorder – approaches, the firm is factoring in revenues for MDD in 2029, Maxim added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DFTX:
- Definium Therapeutics: Late-Stage Pipeline Progress and Upcoming Phase 3 Readouts Support Buy Rating and Favorable Risk-Reward
- Definium Therapeutics Issues Inducement Stock Options to New Hires
- Definium Therapeutics Sets Webcast to Unveil 2025 Results and Business Update
- Definium Therapeutics to Highlight Pipeline at Series of March Investor Conferences
- Definium Therapeutics reports FY25 EPS ($2.06), consensus ($2.00)